National Healthcare Security Administration

Ping An Receives the Two Directors of The Year Awards 2021 from the Hong Kong Institute of Directors

Retrieved on: 
Monday, December 6, 2021
Policy, Patient, Carbon, Technology, Industry, Virginia Portia Royall Inness-Brown, Company, Green, Professional, Board of directors, ESG, Ethics, Ping'an, Integration platform, New Zealander of the Year Awards, Leadership, Risk management, Director, City, Insurance, Communication, Risk, Board, Efficiency, Social responsibility, BET Award for Video Director of the Year, Ecosystem, Award, Internet, SHI, National Healthcare Security Administration, Film, Management

HONG KONG andSHANGHAI, Dec. 6, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) was recognized by the Hong Kong Institute of Directors with two Directors of The Year Awards this year.

Key Points: 
  • HONG KONG andSHANGHAI, Dec. 6, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) was recognized by the Hong Kong Institute of Directors with two Directors of The Year Awards this year.
  • This is Dr. Ma Mingzhe's third time winning the Directors of The Year Awards and Ping An's Board of Directors' fifth time to receive the honor.
  • The Directors of The Year Awards were launched by the Hong Kong Institute of Directors in 2001.
  • Ping An'sBoard of Directors received Directors of the Year Awards in 2007, 2011, 2014 and 2019, and Dr. Ma received Directors of the Year Awards in 2015 and 2019.

Ping An Receives the Two Directors of The Year Awards 2021 from the Hong Kong Institute of Directors

Retrieved on: 
Monday, December 6, 2021
Policy, Patient, Carbon, Technology, Industry, Licht ins Dunkel, Company, Green, Professional, Board of directors, ESG, Ethics, Ping'an, Integration platform, Ernst & Young Entrepreneur of the Year Award, Leadership, Risk management, Director, Forbes Global 2000, City, Fortune, Insurance, Communication, Risk, Board, Efficiency, Social responsibility, BET Award for Video Director of the Year, Fortune Global 500, Ecosystem, Award, Internet, SHI, National Healthcare Security Administration, Forbes, Film, Management

HONG KONG andSHANGHAI, Dec. 6, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) was recognized by the Hong Kong Institute of Directors with two Directors of The Year Awards this year.

Key Points: 
  • HONG KONG andSHANGHAI, Dec. 6, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) was recognized by the Hong Kong Institute of Directors with two Directors of The Year Awards this year.
  • Ping An's Board of Directors won the Board award in the Listed Companies Boards category for its outstanding corporate governance.
  • This is Dr. Ma Mingzhe's third time winning the Directors of The Year Awards and Ping An's Board of Directors' fifth time to receive the honor.
  • The Directors of The Year Awards were launched by the Hong Kong Institute of Directors in 2001.

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

Retrieved on: 
Friday, December 3, 2021
Patient, National Science Board, Cornerstone, CEO, Pegasys, Safety, PD-L1, FASN, Drug, CDC classification system for HIV infection, HKEX, CHB, GBM, Hong Kong Stock Exchange, Occupational Safety and Health Act 1994, Program, Danoprevir, Disease, HCV, National Healthcare, Guideline, Gannex, Degenerative disease, National Healthcare Security Administration, FXR, Cirrhosis, Liver cancer, Hepatitis B virus, PBC, Treatment, Management process, Insurance, Phase, Acne, HIV/AIDS, Conditional sentence, Infection, R, NASH, Hepatitis C, Public health, Mortality, Ravidasvir, Hospital, NRDL, Viral hepatitis, THR, Pharmaceutical industry, Vaccine

HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录（2021）年》) (the "National Reimbursement Drug List" or the "NRDL"). 

Key Points: 
  • The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
  • ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
  • "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
  • Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."

Neusoft Ranks Top in China Healthcare Security Informatization Market

Retrieved on: 
Friday, October 15, 2021
Industry, SSE, IDC, City, Market share, Health care, Education, International Data Group, Medicine, Ecology, National Healthcare Security Administration, Neusoft, Medical device, Health insurance

SHENYANG, China, Oct. 15, 2021 /PRNewswire/ -- According to the Market Shares of Healthcare Security Information System of China 2020: Building a New Healthcare Security Information System recently released by International Data Corporation (IDC)for the first time, Neusoft Corporation("Neusoft", SSE: 600718)ranks the top in the healthcare security information system market of China based on its comprehensive advantages such as deep understanding of the healthcare security industry, stable products and mature industry ecology.

Key Points: 
  • SHENYANG, China, Oct. 15, 2021 /PRNewswire/ -- According to the Market Shares of Healthcare Security Information System of China 2020: Building a New Healthcare Security Information System recently released by International Data Corporation (IDC)for the first time, Neusoft Corporation("Neusoft", SSE: 600718)ranks the top in the healthcare security information system market of China based on its comprehensive advantages such as deep understanding of the healthcare security industry, stable products and mature industry ecology.
  • Neusoft has devoted to developing and promoting healthcare security information systems since 1994, and has continuously innovated the systems along with the reform of healthcare security and medicine & healthcare in China for more than 20 years.
  • Neusoft provides the complete series of healthcare security informatization solutions, including the core handling system of healthcare security, healthcare security public service, fund supervision and decision-making, big data governance and service, and improvement of informatization capability of designated medical institutions, so as to support the healthcare security management authorities to improve the healthcare security services.
  • As of September 2021, Neusoft has participated in the construction of the national and 23 provincial healthcare security information platforms, including the core handling systems of healthcare security in 9 provinces, established healthcare security information systems in more than 200 cities included in the national healthcare security arrangement, and successively launched the provincial systems online in Qinghai, Hainan, Hebei, Gansu, etc.

Global Health Care Security System Market Report 2021: Exponential Increase in Cyber-Attacks During COVID-19 - Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 17, 2021
Technology, Health, Security, Other Health, Health, Health care, Centers for Medicare & Medicaid Services, Roger Hawkins (drummer), System, Growth, Center, Prison on Fire – Life Sentence, Coronavirus, Research, Medicare, NITC, National Healthcare Security Administration, Awareness, PHI, Safety, Zhenhua Data leak, Patient, COVID-19, Theft, Medical device, Pharmaceutical industry

The "Health Care Security System Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Health Care Security System Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The nature of their business poses unique security challenges that can leave them susceptible to theft & internal misuse.
  • In past few years there is rise in cybercrime & activity breaching the access in health care systems.
  • Already overburdened healthcare IT and cyber security teams have been tasked to keep up on these new threats.

Perspectives in Healthcare Security Report: Cybersecurity Reality in Hospitals Not Aligned with Perception

Retrieved on: 
Thursday, August 12, 2021
National Healthcare Security Administration, High Priority, Security theater, Information security, WannaCry ransomware attack, Awareness, Health care, CEO, BioMed Central, Petya (malware), REvil, BlueKeep, HIMSS, Information technology, Partnership, Compliance, Computer security, IOT, Insurance, Hospital, Bottom line, Conference, PST, Philips, Internet, Automation, Risk management, HHS, Health, Solution, Industry, Medical device, Medicine

"With new threat vectors emerging every day, healthcare organizations are facing an unprecedented level of challenges to their security," said Azi Cohen, CEO of CyberMDX. "Hospitals have a lot at stake -- from revenue loss, to reputational damage, and most importantly patient safety. Our new report provides a critical look into the current state of medical device security and will help raise awareness of key issues and disconnects healthcare organizations are facing with their cybersecurity."

Key Points: 
  • The report, done in collaboration with Philips , examines attitudes, concerns, and impacts on medical device security as well as cybersecurity across large and midsize healthcare delivery organizations.
  • "With new threat vectors emerging every day, healthcare organizations are facing an unprecedented level of challenges to their security," said Azi Cohen, CEO of CyberMDX.
  • Our new report provides a critical look into the current state of medical device security and will help raise awareness of key issues and disconnects healthcare organizations are facing with their cybersecurity."
  • "No matter the size, hospitals need to know about their security vulnerabilities," said Maarten Bodlaender, Head of Cyber Security Services at Philips.

Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List

Retrieved on: 
Tuesday, December 29, 2020
National Healthcare Security Administration, State Council of the People's Republic of China, Melanoma

Toripalimab is the first independently developed anti-PD-1 monoclonal antibody in China as well as the first domestic drug to make major breakthroughs in the field of melanoma.

Key Points: 
  • Toripalimab is the first independently developed anti-PD-1 monoclonal antibody in China as well as the first domestic drug to make major breakthroughs in the field of melanoma.
  • As for the future, Junshi Biosciences will strive to develop novel therapeutics, and save lives in China and all over the world with innovations, said Dr. Ning Li, Chief Executive Officer of Junshi Biosciences.
  • In December 2020, toripalimab was included in the NRDL for the treatment of melanoma by the China National Healthcare Security Administration (NHSA).
  • Junshi Biosciences has about 2,000 full time employees in the United States and China, including research and development centers in San Francisco, Maryland, Shanghai, Suzhou, Beijing and Guangzhou.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

Retrieved on: 
Tuesday, December 29, 2020
Finance, Financial markets, Money, National Healthcare Security Administration, State Council of the People's Republic of China, National Roller Derby League, Hong Kong Exchanges and Clearing, Reimbursement, Zai

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).
  • The inclusion of our first NMPA-approved medicine, ZEJULA, in the NRDL is an important step in achieving that mission.
  • NHSA reimbursement will help make ZEJULA affordable to many patients in need across China, said William Liang, Chief Commercial Offer.
  • Zai Lab also conducted a Phase I pharmacokinetic (PK) study of ZEJULA in Chinese patients with ovarian cancer.

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

Retrieved on: 
Monday, December 2, 2019
Companies, Acetic acids, Isoquinolines, Roxadustat, National Roller Derby League, AstraZeneca, National Healthcare Security Administration, Reimbursement, Economy, Business

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).

Key Points: 
  • SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).
  • Inclusion on the NRDL is a significant milestone and inflection point for the growth trajectory for roxadustat, as reimbursement provides affordability and access for patients on a national basis, said Jim Schoeneck, Interim CEO, FibroGen.
  • FibroGen and AstraZeneca will work diligently with provincial governments and hospitals to make this new treatment option available to patients.
  • Roxadustat was among 97 drugs that were included on the updated NRDL list through negotiations, the highest number in history.